Aktie A3D1RX QUALIGEN THERAPEUTICS, INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Qualigen Therapeutics, Inc.

Aktien

A3D1RX

US74754R2022

QLGN

Markt geschlossen - Nasdaq
Andere Börsenplätze
 22:00:00 07.05.2024 		% 5 Tage % 1. Jan.
0,2849 USD -2,73 % Intraday Chart für Qualigen Therapeutics, Inc. -4,97 % -48,20 %
16.04. Marizyme schließt Co-Entwicklungsvertrag mit Qualigen Therapeutics für die Kommerzialisierung des FDA-zugelassenen DuraGraft? CI
08.04. Qualigen Therapeutics, Inc. meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Marizyme Enters into Co-Development Agreement with Qualigen Therapeutics for the Commercialization of FDA-Cleared DuraGraft?
Qualigen Therapeutics' Novel Direct Pan-RAS Inhibitors Presented at American Association of Cancer Research (AACR) 2024 Annual Meeting
Qualigen Therapeutics Announces Poster Featuring Positive Early Clinical Experience with QN-302, a Novel First-in-Class G-Quadruplex Experimental Anti-Cancer Drug, at the American Association of Cancer Research (AACR) 2024 Annual Meeting
Qualigen Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Qualigen Therapeutics, Inc. Enters into A Termination Agreement with Pan-RAS Holdings, Inc
Qualigen Therapeutics, Inc. announced that it has received $0.55 million in funding from Alpha Capital Anstalt
Qualigen Therapeutics, Inc. announced that it expects to receive $0.55 million in funding from Alpha Capital Anstalt
Qualigen Therapeutics, Inc. Enters into A License and Sublicense Agreement with Pan-RAS Holdings, Inc
Qualigen Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Qualigen Therapeutics Provides Corporate Update for Third Quarter and To Date 2023
Qualigen Therapeutics Announces First Patient Dosed in the Phase 1a Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors
Qualigen Therapeutics, Inc. Announces First Patient Dosed in the Phase 1a Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors
Poster Highlighting Qualigen Therapeutics' Pan-RAS Inhibitor Platform Presented at AACR Special Conference: Advances in Breast Cancer
Qualigen Therapeutics Presents Scientific Data on QN-302 at AACR Special Conference: Pancreatic Cancer 2023
Qualigen Therapeutics Partners with TD2 for Phase 1 Clinical Development of QN-302 for the Treatment of Advanced or Metastatic Solid Tumors
Earnings Flash (QLGN) QUALIGEN THERAPEUTICS Reports Q2 Revenue $1.6M
Qualigen Therapeutics, Inc. Reports Financial Results and Corporate Update for Quarter Ending June 30, 2023
Qualigen Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Qualigen Therapeutics Announces US FDA IND Clearance to Initiate Phase 1 Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors
Qualigen Therapeutics Announces UD FDA IND Clearance to Initiate Phase 1 Clinical Trial of Qn-302 for Treatment of Advanced or Metastatic Solid Tumors
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A3D1RX Aktie
  4. Nachrichten Qualigen Therapeutics, Inc.
  5. Andere Sprachen